Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis

• Published in: World journal of gastroenterology : WJG 2019-06, Vol.25 (21), p.2683-2698
• Main Authors: Tantai, Xin-Xing, Yang, Long-Bao, Wei, Zhong-Cao, Xiao, Cai-Lan, Chen, Li-Rong, Wang, Jin-Hai, Liu, Na
• Format: Article
• Language: English
• Subjects: Disease Progression; Hepatic Encephalopathy - epidemiology; Hepatic Encephalopathy - etiology; Humans; Liver Cirrhosis - complications; Liver Cirrhosis - pathology; Meta-Analysis; Observational Studies as Topic; Prognosis; Proton Pump Inhibitors - adverse effects; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v25.i21.2683

Several studies have explored the association between the use of proton pump inhibitors (PPIs) and the risk of developing hepatic encephalopathy (HE) in patients with advanced liver disease. However, the evidence-based conclusions are controversial. We hypothesized that using PPIs may increase the risk of HE in patients with advanced liver disease. If confirmed, clinicians must strictly adhere to the indications for PPI treatment in this population. To evaluate the pooled risk of HE in patients with advanced liver disease who use PPIs. Three electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched from the date of database inception through January 8, 2019 to identify comparative studies evaluating the association between PPI use and the risk of HE. Data from the included studies were extracted. The random-effects model was used for pooling risk estimates and the corresponding 95% confidence intervals (CIs). Subgroup and sensitivity analyses were also performed. In total, 4342 patients from five case-control studies and 188053 patients from four cohort studies were included in this analysis. In patients with advanced liver disease, PPI use was associated with an elevated risk of developing HE, with significant heterogeneity. The pooled odds ratio for case-control studies was 2.58 (95%CI: 1.68-3.94, = 72%). The pooled RR for cohort studies was 1.67 (95%CI: 1.30-2.14, = 67%). The results of the subgroup analyses suggested that the heterogeneity may be the result of differences in the study designs and the definitions of PPI use. The sensitivity and subgroup analyses did not alter our findings. In patients with advanced liver disease, PPI use is associated with an elevated risk of HE. Future large prospective studies are needed to confirm this association.